Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $143.05 billion. The enterprise value is $191.84 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | Jul 25, 2025 |
Share Statistics
Pfizer has 5.69 billion shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 5.69B |
| Shares Outstanding | 5.69B |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 67.71% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 13.28 and the forward PE ratio is 8.90.
| PE Ratio | 13.28 |
| Forward PE | 8.90 |
| PS Ratio | 2.24 |
| Forward PS | 2.32 |
| PB Ratio | 1.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.50 |
| P/OCF Ratio | 9.42 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.83, with an EV/FCF ratio of 15.42.
| EV / Earnings | 17.84 |
| EV / Sales | 3.01 |
| EV / EBITDA | 7.83 |
| EV / EBIT | 10.82 |
| EV / FCF | 15.42 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.16 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | 4.99 |
| Interest Coverage | 6.26 |
Financial Efficiency
Return on equity (ROE) is 12.17% and return on invested capital (ROIC) is 7.18%.
| Return on Equity (ROE) | 12.17% |
| Return on Assets (ROA) | 5.25% |
| Return on Invested Capital (ROIC) | 7.18% |
| Return on Capital Employed (ROCE) | 10.53% |
| Revenue Per Employee | $788,062 |
| Profits Per Employee | $132,741 |
| Employee Count | 81,000 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | -235.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.56% in the last 52 weeks. The beta is 0.44, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -11.56% |
| 50-Day Moving Average | 24.47 |
| 200-Day Moving Average | 25.12 |
| Relative Strength Index (RSI) | 57.92 |
| Average Volume (20 Days) | 45,964,529 |
Short Selling Information
The latest short interest is 107.78 million, so 1.90% of the outstanding shares have been sold short.
| Short Interest | 107.78M |
| Short Previous Month | 111.91M |
| Short % of Shares Out | 1.90% |
| Short % of Float | 1.90% |
| Short Ratio (days to cover) | 2.67 |
Income Statement
In the last 12 months, Pfizer had revenue of $63.83 billion and earned $10.75 billion in profits. Earnings per share was $1.89.
| Revenue | 63.83B |
| Gross Profit | 47.12B |
| Operating Income | 17.74B |
| Pretax Income | n/a |
| Net Income | 10.75B |
| EBITDA | 24.51B |
| EBIT | 17.74B |
| Earnings Per Share (EPS) | $1.89 |
Full Income StatementBalance Sheet
The company has $13.25 billion in cash and $62.04 billion in debt, giving a net cash position of -$48.80 billion or -$8.58 per share.
| Cash & Cash Equivalents | 13.25B |
| Total Debt | 62.04B |
| Net Cash | -48.80B |
| Net Cash Per Share | -$8.58 |
| Equity (Book Value) | 89.01B |
| Book Value Per Share | 15.60 |
| Working Capital | 5.98B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $15.19 billion and capital expenditures -$2.75 billion, giving a free cash flow of $12.44 billion.
| Operating Cash Flow | 15.19B |
| Capital Expenditures | -2.75B |
| Free Cash Flow | 12.44B |
| FCF Per Share | $2.19 |
Full Cash Flow StatementMargins
Gross margin is 73.82%, with operating and profit margins of 27.78% and 16.84%.
| Gross Margin | 73.82% |
| Operating Margin | 27.78% |
| Pretax Margin | 16.50% |
| Profit Margin | 16.84% |
| EBITDA Margin | 38.39% |
| EBIT Margin | 27.78% |
| FCF Margin | 19.49% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 6.84%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.84% |
| Dividend Growth (YoY) | 2.40% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 90.28% |
| Buyback Yield | -0.92% |
| Shareholder Yield | 6.06% |
| Earnings Yield | 7.52% |
| FCF Yield | 8.69% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $29.75, which is 18.24% higher than the current price. The consensus rating is "Hold".
| Price Target | $29.75 |
| Price Target Difference | 18.24% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | -2.56% |
| EPS Growth Forecast (5Y) | 12.79% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.2 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | 8 |